SG11202011964SA - Methods of use of cd24 for the prevention and treatment of leukemia relapse - Google Patents

Methods of use of cd24 for the prevention and treatment of leukemia relapse

Info

Publication number
SG11202011964SA
SG11202011964SA SG11202011964SA SG11202011964SA SG11202011964SA SG 11202011964S A SG11202011964S A SG 11202011964SA SG 11202011964S A SG11202011964S A SG 11202011964SA SG 11202011964S A SG11202011964S A SG 11202011964SA SG 11202011964S A SG11202011964S A SG 11202011964SA
Authority
SG
Singapore
Prior art keywords
prevention
treatment
methods
leukemia relapse
relapse
Prior art date
Application number
SG11202011964SA
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoimmune Inc
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc, Univ Maryland filed Critical Oncoimmune Inc
Publication of SG11202011964SA publication Critical patent/SG11202011964SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
SG11202011964SA 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of leukemia relapse SG11202011964SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862680218P 2018-06-04 2018-06-04
US201862739742P 2018-10-01 2018-10-01
US201862739719P 2018-10-01 2018-10-01
PCT/US2019/035205 WO2019236474A1 (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of leukemia relapse

Publications (1)

Publication Number Publication Date
SG11202011964SA true SG11202011964SA (en) 2020-12-30

Family

ID=68770596

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202011963UA SG11202011963UA (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis
SG11202011964SA SG11202011964SA (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of leukemia relapse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202011963UA SG11202011963UA (en) 2018-06-04 2019-06-03 Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis

Country Status (15)

Country Link
US (2) US20210228680A1 (en)
EP (2) EP3802583A4 (en)
JP (2) JP2021527066A (en)
KR (2) KR20210018294A (en)
CN (2) CN112512640A (en)
AU (2) AU2019282530A1 (en)
BR (2) BR112020024683A2 (en)
CA (2) CA3102372A1 (en)
CL (2) CL2020003168A1 (en)
IL (2) IL279205A (en)
MA (2) MA52810A (en)
MX (2) MX2020013100A (en)
SG (2) SG11202011963UA (en)
TW (2) TW202015753A (en)
WO (2) WO2019236472A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013100A (en) * 2018-06-04 2021-02-17 Oncoimmune Inc Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis.
US20230108492A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating viral pneumonia
WO2023205742A1 (en) * 2022-04-20 2023-10-26 OncoC4, Inc. Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO2009063461A1 (en) 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
PL3260128T3 (en) * 2010-04-28 2021-02-08 Oncoimmune, Inc. Medical use of soluble cd24
CN102250828B (en) * 2010-11-10 2014-11-05 北京大学 CD24 (glycosyl phosphatidyl inositol-linked surface mucin) and new use of CD24 antibody
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
WO2016073704A1 (en) 2014-11-06 2016-05-12 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
CN107531772B (en) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Use of CD24 for reducing low density lipoprotein cholesterol levels
US10799558B2 (en) * 2016-02-02 2020-10-13 Oncoimmune, Inc. Use of CD24 proteins for treating leptin-deficient conditions
MX2020013100A (en) * 2018-06-04 2021-02-17 Oncoimmune Inc Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis.
WO2021142336A1 (en) * 2020-01-08 2021-07-15 Puretech Lyt, Inc. Vesicle compositions for oral delivery

Also Published As

Publication number Publication date
CN112752766A (en) 2021-05-04
IL279205A (en) 2021-01-31
EP3802583A4 (en) 2022-03-16
JP2021527056A (en) 2021-10-11
CA3102374A1 (en) 2019-12-12
EP3801773A4 (en) 2022-03-16
KR20210021317A (en) 2021-02-25
EP3802583A1 (en) 2021-04-14
US20210228680A1 (en) 2021-07-29
MA52811A (en) 2022-03-16
JP2021527066A (en) 2021-10-11
MX2020013100A (en) 2021-02-17
MX2020013103A (en) 2021-05-12
WO2019236472A1 (en) 2019-12-12
MA52810A (en) 2021-04-14
WO2019236474A1 (en) 2019-12-12
CL2020003168A1 (en) 2021-06-11
TW202015753A (en) 2020-05-01
US20210268061A1 (en) 2021-09-02
BR112020024659A2 (en) 2021-03-09
CN112512640A (en) 2021-03-16
US11911441B2 (en) 2024-02-27
CA3102372A1 (en) 2019-12-12
TW202012015A (en) 2020-04-01
KR20210018294A (en) 2021-02-17
IL279204A (en) 2021-01-31
AU2019282044A1 (en) 2021-01-07
AU2019282530A1 (en) 2021-01-07
CL2020003169A1 (en) 2021-06-11
EP3801773A1 (en) 2021-04-14
SG11202011963UA (en) 2020-12-30
BR112020024683A2 (en) 2021-03-09

Similar Documents

Publication Publication Date Title
EP3331525A4 (en) Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
IL279205A (en) Methods of use of cd24 for the prevention and treatment of leukemia relapse
IL279347A (en) Gremlin-1 antagonist for the prevention and treatment of cancer
EP3600393A4 (en) Combination therapy for the treatment of solid and hematological cancers
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
EP3436014A4 (en) Combination therapy for the treatment of acute myeloid leukemia
IL283948A (en) Methods for the treatment of depression
SI3313818T1 (en) Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
IL276363A (en) Combination of sting agonist and il-15/il15-ra for the treatment of cancer
ZA202204657B (en) Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
EP3512560A4 (en) Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
RS64074B1 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
EP3820492A4 (en) Apmv and uses thereof for the treatment of cancer
EP3615020A4 (en) Methods, agents, and compositions for the treatment of acute myeloid leukemia
GB201800736D0 (en) Combination therapy for treatment of leukemia
IL277749A (en) Pladienolide compounds and their use
IL280262A (en) Compositions and methods for the treatment of cancer
IL284124A (en) Quinoline derivatives for use in the treatment or prevention of cancer
IL282313A (en) Abituzumab for the treatment of colorectal cancer
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
EP3535025A4 (en) Compositions and methods for treating patients suffering from glioma or leukemia
HK1257911A1 (en) Use of 7,8-dihydroxyflavone for treatment or prevention of cognitive decline associated with aging
EP3603635A4 (en) Use of melatonin for the treatment of tumours
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency